Year
2023
-
FDA panel backs AZ’s PT027 asthma rescue drug, but in adults only
-
Pharmacogenomics Offers a Glimpse Into the Future of Pharmacy
-
UK Allows Interchangeability of Biosimilars
-
FDA Grants Sobi Emergency Authorization for Kineret to Treat COVID-19
-
EQRx Drops U.S. Plans for NSCLC Therapy
-
FDA Approves AstraZeneca’s Imfinzi and Imjudo for Stage 4 NSCLC
-
Stada and Xbrane Get EU Approval for Lucentis Biosimilar for Eye Disease
-
FDA Accepts New Drug Application for Zilucoplan for Generalized Myasthenia Gravis
-
Satsuma STS101 Migraine Candidate Fails Late-Stage Trial
-
GSK Limits Ovarian Cancer Drug’s Indication